Table 1. Baseline Cohort Characteristics by Time-Varying Treatment Exposures.
| Characteristic | No. (%) | |||
|---|---|---|---|---|
| Full cohort (n = 93 746) | Topical calcineurin inhibitor (n = 7033) | Topical corticosteroid only (n = 73 674) | Unexposed (n = 46 141)a | |
| Age at AD diagnosis, y | ||||
| 40-49 | 28 666 (30.6) | 2577 (36.6) | 22 072 (30.0) | 14 050 (30.5) |
| 50-59 | 27 389 (29.2) | 2257 (32.1) | 21 625 (29.4) | 13 274 (28.8) |
| 60-69 | 18 878 (20.1) | 1346 (19.1) | 15 107 (20.5) | 9349 (20.3) |
| 70-79 | 12 124 (12.9) | 640 (9.1) | 9861 (13.4) | 5973 (12.9) |
| ≥80 | 6689 (7.1) | 213 (3.0) | 5009 (6.8) | 3495 (7.6) |
| Sex | ||||
| Women | 55 023 (58.7) | 4967 (70.6) | 43 800 (59.5) | 26 916 (58.3) |
| Men | 38 723 (41.3) | 2066 (29.4) | 29 874 (40.5) | 19 225 (41.7) |
| Race/ethnicity | ||||
| White | 47 317 (50.5) | 3285 (46.7) | 36 422 (49.4) | 24 240 (52.5) |
| Asian | 19 281 (20.6) | 1711 (24.3) | 15 726 (21.3) | 8904 (19.3) |
| Hispanic | 11 400 (12.2) | 835 (11.9) | 9126 (12.4) | 5387 (11.7) |
| Black | 7444 (7.9) | 632 (9) | 6047 (8.2) | 3523 (7.6) |
| Multiracial | 4711 (5.0) | 391 (5.6) | 3835 (5.2) | 2344 (5.1) |
| Native American | 408 (0.4) | 32 (0.5) | 316 (0.4) | 201 (0.4) |
| Unknown/other | 3185 (3.4) | 147 (2.1) | 2202 (3.0) | 1542 (3.3) |
| Keratinocyte carcinoma historyb | 4464 (4.8) | 189 (2.7) | 3198 (4.3) | 2429 (5.3) |
| Previous AD immunosuppressionc | 1001 (1.1) | 87 (1.2) | 800 (1.1) | 523 (1.1) |
| Previous systemic corticosteroid used | 85 (0.1) | 6 (0.1) | 69 (0.1) | 39 (0.1) |
| Cohort entry year, mean (SD), y | 2006 (3.3) | 2006 (3.3) | 2006 (3.3) | 2006 (3.4) |
Abbreviation: AD, atopic dermatitis.
a
Defined as no dispensed prescriptions for topical calcineurin inhibitor or topical corticosteroids.
b
Defined as having ever been diagnosed with a pathologic test-proven basal cell carcinoma or squamous cell carcinoma before cohort entry.
c
Pharmacy-dispensed prescriptions for systemic immunosuppressive agents including cyclosporine, tacrolimus, methotrexate, and tumor necrosis factor inhibitors (adalimumab, etanercept, and infliximab) in the 2 years before cohort entry.
d
Pharmacy-dispensed prescriptions for oral or intravenous corticosteroids in the 2 years before cohort entry.